This clinical trial, sponsored by Amgen, evaluates the efficacy and safety of pegfilgrastim compared to filgrastim for PBPC mobilization in patients with Hodgkin's and non-Hodgkin's lymphoma. Given the established market for G-CSF products, including filgrastim, pegfilgrastim's longer-acting formulation may provide a competitive advantage in terms of patient compliance and treatment convenience. The trial's completion in 2004 positions Amgen to leverage potential market exclusivity and enhance its portfolio in hematology and oncology, particularly in the context of autologous stem cell transplantation. The results could influence treatment guidelines and establish pegfilgrastim as a preferred option, impacting market dynamics and competitive positioning.